Author:
Berger Audrey,Vingerhoets Marie,Gelb Arnaud,Muller Georges,Bonzon David
Reference10 articles.
1. Welch JT, Arden NS (2019) Considering “clonality”: a regulatory perspective on the importance of the clonal derivation of mammalian cell banks in biopharmaceutical development. Biologicals 62:16–21. https://doi.org/10.1016/j.biologicals.2019.09.006
2. Lai T, Yang Y, Ng SK (2013) Advances in mammalian cell line development technologies for recombinant protein production. Pharmaceuticals (Basel, Switzerland) 6:579–603. https://doi.org/10.3390/ph6050579
3. European Medicines Agency (1998) Quality of biotechnological products: derivation and characterisation of cell substrates used for production of biotechnological/biological products. ICH Harmonised Tripartite Guideline. Dev Biol Stand 93:223–234
4. Chen C, Le K, Le H et al (2020) Methods for estimating the probability of clonality in cell line development. Biotechnol J 15:1900289. https://doi.org/10.1002/biot.201900289
5. Bonzon D, Muller G, Bureau J-B et al (2020) Impedance-based single-cell pipetting, vol 25. SLAS Technology: Translating Life Sciences Innovation, pp 222–233. https://doi.org/10.1177/2472630320911636